// App-Quantinova.ai

: Impact of Induction Chemotherapy and Primary CNS Prophylaxis on Outcomes in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements (HGBL-DH/TH) or HGBL-NOS: An International Multi-Center Retrospective Analysis

Researchers

Presenter

  • John R Balendra

Principal Investigators

  • Alexander Glover

  • Liu Xin

  • Sanjay De Mel

  • Anand Jeyasekharan

  • Stephen G Jones

  • Mark Bishton

  • Chan Y. Cheah

Medical Centers

  • Department of Clinical Haematology,Sir Charles Gairdner Hospital,Nedlands,Australia

  • Department of Haematology, Pathwest Laboratory Medicine, Nedlands, Australia

  • School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley, Western Australia, Australia

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • National University Health System, Department of Haematology Oncology, National University Cancer Institute,, Singapore, SGP

  • Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore, Singapore

  • Department of Haematology, Sherwood Forest Hospitals NHS Trust, Sutton-in-Ashfield, United Kingdom

  • Department of Clinical Haematology,Sir Charles Gairdner Hospital,Nedlands,Australia

Locations

  • Australia

  • United Kingdom

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • B-cell lymphoma 2

  • B-cell lymphoma 6

  • cMYC

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved